TCON | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 19%

Liquidity 39%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

-21.33%

6 Months

-94.22%

1 Year

-54.86%

2 Year

-94.26%

Key data

Stock price

$1.43

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$0.07 - $12.40

52 WEEK CHANGE

-$52.83

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

3.408 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Charles P. Theuer
Region: US
Website: traconpharma.com
Employees: 20
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

TRACON Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody. TRC102, a small molecule that is in Phase II clinical trial for the. treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and gliob

TCON - Tracon Pharmaceuticals, Inc.